Abstract: The use of phosphatidylserine as a target for treating inflammatory bowel disease. Phosphatidylserine can be used as a marker of inflammatory bowel disease and used for drug screening. Annexin A5 can be traced by phosphatidylserine in the extracellular membrane and indicate the location of lesions and extent of inflammatory bowel disease, and can be used to treat inflammatory bowel disease. Better anti-inflammatory effects can be generated by mutating Annexin A5.

Abstract: Curcumin and a pharmaceutically acceptable salt thereof are used in the preparation of drugs for antitumor associated syndrome. Also disclosed is the use of curcumin to improve anemia while inhibiting tumors.

Abstract: A proteomic screening method for anaerobic-specific and expression-effective promoter, and a method of specially delivering and selectively stably expressing target gene in anaerobic tissue by an alcohol dehydrogenase promoter and uses thereof. The latter comprises an anaerobically-induced alcohol dehydrogenase promoter which is used as target gene promoter, anaerobic target bacteria and low copy number plasmid. Therefore, the target gene can be specially and highly expressed under hypoxia condition in vivo or in vitro. The selective gene expression which is driven by the alcohol dehydrogenase promoter in anaerobic tissue can be used as gene therapy method to treat anaerobic tissue disease including tumor, or to prepare anti-tumor drug.

Abstract: Provided is a fusion protein comprising a tumor necrosis factor related apoptosis inducing ligand (TRAIL), integrin ligands of ?V?3 and ?V?5 and a linking peptide. Also provided are the expression method and simple separation and purification process for the production of the fusion protein which is soluble and has high content of the polymer, and use of the fusion protein for the manufacturing of a medicament for the treatment of tumor. The fusion protein has good tumor tissue targeting property, significantly enhanced anti-tumor effect, which can also reduce the dose of the needed protein for the target treatment effect, improve the bioavailability, reduce the treatment cost, decrease and overcome the potential toxic and side effects of the tumor necrosis factor-related apoptosis inducing ligand.

Abstract: The invention provides the design, preparation methods and applications of the variant of annexin V. The variant of annexin V is the protein with amino acid residue sequence in sequence 1 in the SEQUENCE LISTING, characterized in that it is the protein derived from sequence 1 by one or several amino acid residues of the sequence 1 being substituted, missing or being added and its amino acid residues have the same activity with the sequence of the sequence 1. The variant protein of the annexin V prepared form the preparation methods of the variant of the annexin V has high purity, high productivity, high labeling efficiency and stability, without effect to the biological function of the variant of the annexin V, which is applicable to industrial production and allows for further research of the variant of the annexin V.

Abstract: The invention provides the design, preparation methods and applications of the variant of annexin V. The variant of annexin V is the protein with amino acid residue sequence in sequence 1 in the SEQUENCE LISTING, characterized in that it is the protein derived from sequence 1 by one or several amino acid residues of the sequence 1 being substituted, missing or being added and its amino acid residues have the same activity with the sequence of the sequence 1. The variant protein of the annexin V prepared form the preparation methods of the variant of the annexin V has high purity, high productivity, high labeling efficiency and stability, without effect to the biological function of the variant of the annexin V, which is applicable to industrial production and allows for further research of the variant of the annexin V.

Abstract: A proteomic screening method for anaerobic-specific and expression-effective promoter, and a method of specially delivering and selectively stably expressing target gene in anaerobic tissue by an alcohol dehydrogenase promoter and uses thereof. The latter comprises an anaerobically-induced alcohol dehydrogenase promoter which is used as target gene promoter, anaerobic target bacteria and low copy number plasmid. Therefore, the target gene can be specially and highly expressed under hypoxia condition in vivo or in vitro. The selective gene expression which is driven by the alcohol dehydrogenase promoter in anaerobic tissue can be used as gene therapy method to treat anaerobic tissue disease including tumor, or to prepare anti-tumor drug.

Abstract: The invention belongs to the field of genetic engineering and biotechnology, and specifically discloses a design, preparation and pharmic application of a tumor-targeted TNF-related apoptosis-inducing ligand's variant. The tumor-targeted TNF-related apoptosis-inducing ligand's variant is generated by a fused protein which is consisted of the ligand of CD13, the connecting peptide and TNF-related apoptosis-inducing ligand's variant, and which is by the construction of coding gene of the variant according to the technology of genetic engineering and clone, soluble recombinant expression and ordinary separation and purification. The variant, produced by the method of preparation of the tumor-targeted TNF-related apoptosis-inducing ligand's variant, has favorable tumor-targeting characteristics and the significant enhancement of the anti-tumor effect.

Abstract: Provided is a fusion protein comprising a tumor necrosis factor related apoptosis inducing ligand (TRAIL), integrin ligands of ?V?3 and ?V?5 and a linking peptide. Also provided are the expression method and simple separation and purification process for the production of the fusion protein which is soluble and has high content of the polymer, and use of the fusion protein for the manufacturing of a medicament for the treatment of tumor. The fusion protein has good tumor tissue targeting property, significantly enhanced anti-tumor effect, which can also reduce the dose of the needed protein for the target treatment effect, improve the bioavailability, reduce the treatment cost, decrease and overcome the potential toxic and side effects of the tumor necrosis factor-related apoptosis inducing ligand.

Abstract: The present invention relates to the field of biotechnology. The invention provides a novel approach using tobacco mosaic virus omega leader sequence to enhance the solubility of the recombinant products in E. coli and the method of use therefore. The invention provides the utilization of tobacco mosaic virus omega leader sequence into E. coli expression vector, and the tobacco mosaic virus omega leader sequence containing expression vector can be used in combination with other available means to obtain higher expression or better solubility. The invention can be applied to biotechnological pharmaceutical industry, genetic engineering, biochemistry and molecular biology etc. The invention provides an expression vector pTORG, which is a highly efficient GST fusion expression vector, and can significantly enhance the yield of biologically active recombinant products.

Abstract: The present invention relates to the field of biotechnology. The invention provides a novel approach using tobacco mosaic virus omega leader sequence to enhance the solubility of the recombinant products in E. coli and the method of use therefore. The invention provides the utilization of tobacco mosaic virus omega leader sequence into E. coli expression vector, and the tobacco mosaic virus omega leader sequence containing expression vector can be used in combination with other available means to obtain higher expression or better solubility. The invention can be applied to biotechnological pharmaceutical industry, genetic engineering, biochemistry and molecular biology etc. The invention provides an expression vector pTORG, which is a highly efficient GST fusion expression vector, and can significantly enhance the yield of biologically active recombinant products.